185 related articles for article (PubMed ID: 37278880)
1. Management of Drug Interactions with Inducers: Onset and Disappearance of Induction on Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyltransferase 1A1 Substrates.
Bettonte S; Berton M; Stader F; Battegay M; Marzolini C
Eur J Drug Metab Pharmacokinet; 2023 Jul; 48(4):353-362. PubMed ID: 37278880
[TBL] [Abstract][Full Text] [Related]
2. Physiologically Based Pharmacokinetic Modeling of Doravirine and Its Major Metabolite to Support Dose Adjustment With Rifabutin.
Yee KL; Cabalu TD; Kuo Y; Fillgrove KL; Liu Y; Triantafyllou I; McClain S; Dreyer D; Wenning L; Stoch SA; Iwamoto M; Sanchez RI; Khalilieh SG
J Clin Pharmacol; 2021 Mar; 61(3):394-405. PubMed ID: 32989795
[TBL] [Abstract][Full Text] [Related]
3. Physiologically-Based Pharmacokinetic Modeling to Support the Clinical Management of Drug-Drug Interactions With Bictegravir.
Stader F; Battegay M; Marzolini C
Clin Pharmacol Ther; 2021 Nov; 110(5):1231-1239. PubMed ID: 33626178
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic Modeling of the Drug-Drug Interaction Between Efavirenz and Dolutegravir: Is This Interaction Clinically Relevant When Switching From Efavirenz to Dolutegravir During Pregnancy?
Dallmann A; van den Anker J; Ahmadzia HK; Rakhmanina N
J Clin Pharmacol; 2023 Jun; 63 Suppl 1():S81-S95. PubMed ID: 37317489
[TBL] [Abstract][Full Text] [Related]
5. Physiologically Based Pharmacokinetic Modeling of the Drug-Drug Interaction Between CYP3A4 Substrate Glasdegib and Moderate CYP3A4 Inducers in Lieu of a Clinical Study.
Callegari E; Tse S; Doran AC; Goosen TC; Shaik N
J Clin Pharmacol; 2024 Jan; 64(1):80-93. PubMed ID: 37731282
[TBL] [Abstract][Full Text] [Related]
6. Predicting the Effect of CYP3A Inducers on the Pharmacokinetics of Substrate Drugs Using Physiologically Based Pharmacokinetic (PBPK) Modeling: An Analysis of PBPK Submissions to the US FDA.
Wagner C; Pan Y; Hsu V; Sinha V; Zhao P
Clin Pharmacokinet; 2016 Apr; 55(4):475-83. PubMed ID: 26369776
[TBL] [Abstract][Full Text] [Related]
7. Physiologically-based pharmacokinetic modeling for mirabegron: a multi-elimination pathway mediated by cytochrome P450 3A4, uridine 5'-diphosphate-glucuronosyltransferase 2B7, and butyrylcholinesterase.
Konishi K; Minematsu T; Nagasaka Y; Tabata K
Xenobiotica; 2019 Aug; 49(8):912-921. PubMed ID: 30301385
[TBL] [Abstract][Full Text] [Related]
8. Management of Drug-Drug Interactions Between Long-Acting Cabotegravir and Rilpivirine and Comedications With Inducing Properties: A Modeling Study.
Bettonte S; Berton M; Stader F; Battegay M; Marzolini C
Clin Infect Dis; 2023 Apr; 76(7):1225-1236. PubMed ID: 36377436
[TBL] [Abstract][Full Text] [Related]
9. Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P-glycoprotein-cytochrome P450 3A4 dual substrates.
Pan X; Yamazaki S; Neuhoff S; Zhang M; Pilla Reddy V
CPT Pharmacometrics Syst Pharmacol; 2021 Dec; 10(12):1485-1496. PubMed ID: 34729944
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
[TBL] [Abstract][Full Text] [Related]
11. Guidance for Rifampin and Midazolam Dosing Protocols To Study Intestinal and Hepatic Cytochrome P450 (CYP) 3A4 Induction and De-induction.
Kapetas AJ; Sorich MJ; Rodrigues AD; Rowland A
AAPS J; 2019 Jun; 21(5):78. PubMed ID: 31218462
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects.
Zahir H; Greenberg J; Shuster D; Hsu C; Watanabe K; LaCreta F
Clin Pharmacokinet; 2022 Nov; 61(11):1623-1639. PubMed ID: 36264536
[TBL] [Abstract][Full Text] [Related]
13. CYP3A4-mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1-mediated effects on bilirubin glucuronidation in humans.
Chattopadhyay N; Kanacher T; Casjens M; Frechen S; Ligges S; Zimmermann T; Rottmann A; Ploeger B; Höchel J; Schultze-Mosgau MH
Br J Clin Pharmacol; 2018 Dec; 84(12):2857-2866. PubMed ID: 30171692
[TBL] [Abstract][Full Text] [Related]
14. Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration.
Baneyx G; Parrott N; Meille C; Iliadis A; Lavé T
Eur J Pharm Sci; 2014 Jun; 56():1-15. PubMed ID: 24530864
[TBL] [Abstract][Full Text] [Related]
15. Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover.
Qian CQ; Zhao KJ; Chen Y; Liu L; Liu XD
Eur J Pharm Sci; 2019 Jun; 134():194-204. PubMed ID: 31047967
[TBL] [Abstract][Full Text] [Related]
16. Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.
Marzolini C; Rajoli R; Battegay M; Elzi L; Back D; Siccardi M
Clin Pharmacokinet; 2017 Apr; 56(4):409-420. PubMed ID: 27599706
[TBL] [Abstract][Full Text] [Related]
17. Comparative effects of rifabutin and rifampicin on cytochromes P450 and UDP-glucuronosyl-transferases expression in fresh and cryopreserved human hepatocytes.
Reinach B; de Sousa G; Dostert P; Ings R; Gugenheim J; Rahmani R
Chem Biol Interact; 1999 Jun; 121(1):37-48. PubMed ID: 10418969
[TBL] [Abstract][Full Text] [Related]
18. Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro/in vivo correlation.
Brainard DM; Kassahun K; Wenning LA; Petry AS; Liu C; Lunceford J; Hariparsad N; Eisenhandler R; Norcross A; DeNoia EP; Stone JA; Wagner JA; Iwamoto M
J Clin Pharmacol; 2011 Jun; 51(6):943-50. PubMed ID: 20852006
[TBL] [Abstract][Full Text] [Related]
19. Drug-Drug Interaction Studies to Evaluate the Effect of Inhibition of UGT1A1 and CYP3A4 and Induction of CYP3A4 on the Pharmacokinetics of Tropifexor in Healthy Subjects.
Chen J; Stringer R; Shah B; Gu J; Zhang Y; Hackling M; Prince W; Woessner R
Clin Pharmacol Drug Dev; 2022 Nov; 11(11):1253-1263. PubMed ID: 35962468
[TBL] [Abstract][Full Text] [Related]
20. Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.
Umehara K; Huth F; Jin Y; Schiller H; Aslanis V; Heimbach T; He H
Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
